Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

▤ Summary

Mabwell shared new clinical data for its Nectin-4-targeting ADC 9MW2821 at the 2026 ESMO Gynaecological Cancers Congress. The results showed manageable safety and promising efficacy in recurrent or metastatic cervical cancer, including stronger responses in patients who had already received immunotherapy. Mabwell also presented early combination data for 9MW2821 with toripalimab, which showed a high response rate in the treatment-naive subgroup. The company says four pivotal Phase III studies are underway and that it expects interim analyses and pre-NDA meeting requests in 2026.

▦ Linked Companies